German ZEW: A first glimpse of the consequences of the second nationwide lockdown German ZEW: A first glimpse of the consequences of the second nationwide lockdown German ZEW: A first glimpse of the consequences of the second nationwide lockdown

German ZEW: A first glimpse of the consequences of the second nationwide lockdown

Macro
CD
Christopher Dembik

Head of Macro Analysis

Summary:  The German November ZEW Survey is at the top of the economic calendar today, but it did not really drive market sentiment as investors are still focusing on Pfizer vaccine news and hopes of swifter economic recovery in 2021.


Today’s German November ZEW report is one of the most important data set released this week. It gives us a first glimpse of the consequences of the second nationwide lockdown on economic expectations. Aligned with consensus, all the main components of the survey for November are declining, reflecting the impact of the new partial lockdown or light lockdown decided by the German government to contain the second wave of the virus. The current situation assessment is deteriorating again, sliding 4.8 points to land at minus 64.3 versus expected at minus 65. Without much surprise, many panelist mentioned as a key concern the economic uncertainty related to the virus and the poor financial situation of the banking sector and insurers due to the low growth and low interest rates environment and risks of rising non-performing loans in coming months. This is not really new, but it will certainly continue to weight on the panelists’ mood in the coming months as long as there is no better economic visibility.

Looking into details, there are clear indications in the report that the German economy is once again edging closer to recession territory. Economic expectations, which are the most watched components of the report, are edging down again. In November, the subindex recorded a massive drop of 19.5 points to 32.8, but it is still standing way above its long-term average of 19.5. Unlike what has happened during the previous lockdown that occurred last Spring, we don’t see a general decline in economic sentiment across all the sectors. Firms most exposed to the new restrictions (mostly in the services sector and in the construction sector) are experiencing a new deterioration in economic sentiment. The subindex for the services sector is down at 21.8 vs prior at 26.7 and the subindex for the construction sector is also falling, at 14.3 vs prior at 16.6. In contrast, all the other sectors are going through stabilization (such as the utilities sector) or are heading north (automobile, mechanical engineering and chemicals/pharmaceuticals). This gap in economic sentiment is not only indicating that some firms are less hit by restrictions than in the first lockdown but also that higher foreign demand, especially from Asia/China, is fueling increased optimism in the German manufacturing sector. It thus confirms that economic contraction in Q4 will be less important than in Q2 as business continues more or less as normal in the manufacturing sector.

There is light at the end of the tunnel. The survey has been conducted before Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study yesterday. It was undoubtedly positive and unexpected news, though it is still too early at that stage to know the exact implications of these announcements. There are still a lot of pending questions such as whether the vaccine will prevent transmission of COVID-19 or how many doses will be necessary etc. That being said, the increased likelihood of an imminent vaccine might have positive trigger effects on consumers and some firms. Most of the economic damage related to the pandemic mostly results from the fear of the virus, not the virus itself. Therefore, if there is credible hope of economic normalization in 2021, perhaps in the first semester, we can expect to see in coming months an improvement in sentiment survey, including in the ZEW survey. Most firms that are currently going through turmoil, typically hairdressers, will get a decisive boost from the vaccine and will be able to see demand going back to normal almost immediately afterwards. That’s why we should not overstate the impact of today’s ZEW report and, in that sense, the market was certainly right not to pay too much attention to it.

Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.